Summit Therapeutics Inc. (SMMT) Revenue History
Annual and quarterly revenue from 2003 to present
SMMT Revenue Over Time (2003–2025)
SMMT Revenue Growth History
14 of 20 years with positive growth- FY2003 revenue growth
- N/A
- FY2004 revenue growth
- +11564.5%
- FY2005 revenue growth
- +345.5%
- FY2006 revenue growth
- +113.9%
- FY2007 revenue growth
- +197.1%
- FY2008 revenue growth
- -95.6%
- FY2009 revenue growth
- +13.2%
- FY2010 revenue growth
- +144.7%
- FY2011 revenue growth
- +51.1%
- FY2012 revenue growth
- +69.8%
- FY2013 revenue growth
- -2.7%
- FY2014 revenue growth
- +2.4%
- FY2015 revenue growth
- -32.2%
- FY2016 revenue growth
- +85.5%
- FY2017 revenue growth
- +496.3%
- FY2018 revenue growth
- +302.9%
- FY2019 revenue growth
- -98.9%
- FY2020 revenue growth
- +2.8%
- FY2021 revenue growth
- +112.7%
- FY2022 revenue growth
- -56.4%
- FY2023 revenue growth
- -100.0%
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $0 | — |
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2022)
SMMT's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
By Geography
SMMT Revenue Analysis (2003–2025)
Current Revenue & Growth
As of November 8, 2026, Summit Therapeutics Inc. (SMMT) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q2 2026) recorded $0 in revenue
Historical Growth Trajectory
SMMT's historical revenue data shows various trends over time. Summit Therapeutics Inc.'s highest annual revenue of $57.1 million was recorded in 2018.
Revenue by Segment
SMMT's revenue is primarily driven by License and Service (100%). With over half of revenue concentrated in License and Service, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including KYMR (+133.7% YoY), TNGX (+121.5% YoY), and KRYS (+26.0% YoY). Compare SMMT vs KYMR →
SMMT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SMMTCurrent | $0 | - | - | - | |
 KYMR | $39M | +133.7% | +2.9% | -891.3% | |
 TNGX | $62M | +121.5% | +52.1% | -178.4% | |
 KRYS | $389M | +26.0% | - | 41.5% |
SMMT Historical Revenue Data (2003–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-1,094,374,000 | - |
| 2024 | $0 | - | $0 | - | $-180,513,000 | - |
| 2023 | $0 | -100.0% | $0 | - | $-478,227,000 | - |
| 2022 | $583K | -56.4% | $583K | 100.0% | $-59,633,462 | -10225.4% |
| 2021 | $1.3M | +112.7% | $1.3M | 100.0% | $-63,731,961 | -4764.3% |
| 2020 | $629K | +2.8% | $629K | 100.0% | $-71,646,000 | -11392.7% |
| 2019 | $612K | -98.9% | $612K | 100.0% | $-22,624,463 | -3697.6% |
| 2018 | $57.1M | +302.9% | $56.4M | 98.8% | $5.4M | 9.4% |
| 2017 | $14.2M | +496.3% | $14.2M | 100.0% | $-25,829,000 | -182.3% |
| 2016 | $2.4M | +85.5% | $2.4M | 100.0% | $-24,853,000 | -1046.0% |
| 2015 | $1.3M | -32.2% | $1.3M | 100.0% | $-20,346,000 | -1588.3% |
| 2014 | $1.9M | +2.4% | $1.9M | 100.0% | $-12,233,000 | -647.9% |
| 2013 | $1.8M | -2.7% | $1.8M | 100.0% | $-6,709,000 | -363.8% |
| 2012 | $1.9M | +69.8% | $1.9M | 100.0% | $-4,577,000 | -241.5% |
| 2011 | $1.1M | +51.1% | $1.1M | 100.0% | $-4,714,047 | -422.3% |
SMMT Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
23+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SMMT — Frequently Asked Questions
Quick answers to the most common questions about buying SMMT stock.
Is SMMT's revenue growth accelerating or slowing?
SMMT TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is SMMT's revenue history from 2003 to 2026?
Summit Therapeutics Inc. (SMMT) revenue history spans 2003 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is SMMT's long-term revenue growth rate (CAGR)?
Summit Therapeutics Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for SMMT.
Why does SMMT's quarterly revenue fluctuate?
SMMT quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Summit Therapeutics Inc.'s revenue data from 2003 to 2026 shows full historical quarterly detail on this page.
How is SMMT's revenue distributed by segment?
SMMT reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does SMMT's revenue compare to industry peers?
Summit Therapeutics Inc. (SMMT) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.